

SECURITY CLASSIFICATION OF THIS PAGE

Form Approved
OMB No. 0704-0188

REPORT DOCUMENTATION PAGE

1a. REPORT SECURITY CLASSIFICATION UNCLASSIFIED			1b. RESTRICTIVE MARKINGS		
2a. SECURITY			3. DISTRIBUTION / AVAILABILITY OF REPORT Approved for public release: distribution unlimited.		
2b. DECLASSIF					
4. PERFORMIN AD-A232 936			5. MONITORING ORGANIZATION REPORT NUMBER(S)		
6a. NAME OF PERFORMING ORGANIZATION Dept of Immunology Division of CD&I		6b. OFFICE SYMBOL (if applicable) SGRD-UWF-D	7a. NAME OF MONITORING ORGANIZATION Walter Reed Army Institute of Research Walter Reed Army Medical Center		
6c. ADDRESS (City, State, and ZIP Code)			7b. ADDRESS (City, State, and ZIP Code) Library Reprint Department Washington, DC 20307-5100		
8a. NAME OF FUNDING / SPONSORING ORGANIZATION WRAIR		8b. OFFICE SYMBOL (if applicable)	9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER		
8c. ADDRESS (City, State, and ZIP Code)			10. SOURCE OF FUNDING NUMBERS		
			PROGRAM ELEMENT NO.	PROJECT NO.	TASK NO.
					WORK UNIT ACCESSION NO.
11. TITLE (Include Security Classification) Safety and Immuogenicity of a Plasmodium Vivax sporozoite vaccine.					
12. PERSONAL AUTHOR(S) Dr. Gordon, Thomas M. Cosgriff, Imogene Schneider, Gail F. Wasserman, William					
Maierian, Michael Hollingdale, and Jeffery D. Chulav					
13a. TYPE OF REPORT		13b. TIME COVERED FROM TO		14. DATE OF REPORT (Year, Month, Day) 1990 May 09	
				15. PAGE COUNT	
16. SUPPLEMENTARY NOTATION					
17. COSATI CODES			18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)		
FIELD	GROUP	SUB-GROUP			
19. ABSTRACT (Continue on reverse if necessary and identify by block number) A recombinant DNA Plasmodium Vivax sporozoite vaccine containing the repeating region of the Savavador I strain circumsporozoite (CS) protein was produced in Eschichia coli.					
20. DISTRIBUTION / AVAILABILITY OF ABSTRACT <input checked="" type="checkbox"/> UNCLASSIFIED/UNLIMITED <input type="checkbox"/> SAME AS RPT. <input type="checkbox"/> DTIC USERS					
22a. NAME OF RESPONSIBLE INDIVIDUAL Brenda L. Birk, SGT			21. ABSTRACT SECURITY CLASSIFICATION UNCLASSIFIED		
			22b. TELEPHONE (Include Area Code) 301-576-3659		22c. OFFICE SYMBOL SGRD-UWF-D

DTIC
ELECTE
MAR 12 1991
S G D

SAFETY AND IMMUNOGENICITY OF A *PLASMODIUM VIVAX* SPOROZOITE VACCINE

DANIEL M. GORDON, THOMAS M. COSGRIFF, IMOGENE SCHNEIDER,
GAIL F. WASSERMAN, WILLIAM R. MAJARIAN, MICHAEL R. HOLLINGDALE,
AND JEFFREY D. CHULAY

Walter Reed Army Institute of Research, Washington, DC; United States Army Medical Institute
of Infectious Diseases, Fort Detrick, Maryland; SmithKline Beecham Pharmaceuticals,
Swedeland, Pennsylvania; Biomedical Research Institute, Rockville, Maryland

Abstract. A recombinant DNA *Plasmodium vivax* sporozoite vaccine containing the repeating region of the Salvador I strain circumsporozoite (CS) protein was produced in *Escherichia coli*. This vaccine was tested in 13 naive volunteers at doses of 10–1,000 µg. No serious adverse reactions were noted. None of 4 volunteers receiving the 10 µg dose developed antibodies measurable by ELISA. Six of 9 volunteers in the other dose groups developed measurable antibodies: 5 of 5 volunteers receiving 100 µg and 1 of 4 receiving 1,000 µg. Antibody responses measured by immunofluorescence assays paralleled those seen by ELISA. None of the volunteers developed antisera that inhibited sporozoite invasion of human hepatoma cells in vitro. Lack of a classical anamnestic response and lack of a typical dose response to increasing amounts of antigen suggests the possible presence of an immunosuppressive epitope in the repetitive region of the CS protein.

The immunodominant protein covering the surface of malaria sporozoites, the circumsporozoite (CS) protein, continues to be a major target in the development of an effective anti-sporozoite malaria vaccine. Animals and humans immunized with irradiated sporozoites develop antibodies directed against the respective CS protein and are protected against infection when challenged with sporozoites administered either iv or by mosquito bite.¹⁻³ Passive transfer of monoclonal antibodies (Mabs) directed against the immunodominant repeat region of the *Plasmodium berghei* CS protein can confer protection, in a dose dependent fashion, to recipient animals subsequently challenged with viable sporozoites.^{4,5} These data have provided the impetus to develop and test subunit vaccines designed to elicit antibodies to the repeating NANP/NVDP epitope found in the *P. falciparum* CS protein.^{6,7} The gene which codes for the CS protein of *P. vivax* has also been cloned and sequenced, and the amino acid sequence of the sporozoite surface protein deduced.^{8,9} The CS protein of *P. vivax* is analogous to other CS proteins and contains a highly charged region near the amino terminus followed by an area of repeating amino acids. In *P. vivax*, the immunodominant region consists of 20 tandem repeats of the 9 amino acid sequence Gly-Asp-Arg-Ala-(Asp/Ala)-Gly-Gin-Pro-Ala (GDRA D/A

GQPA). A fragment of the gene encoding the 20 tandem repeats (V20) has been cloned into *Escherichia coli*¹⁰ and expressed as a fusion protein with NS1₈₁ (81 amino acids from the N-terminus of the nonstructural protein NS1 of influenza A virus). NS1₈₁ was chosen as part of the fusion protein with the *P. vivax* repeat region because it may provide T cell epitopes important in the induction of cell mediated immunity.¹⁰ The NS 1₈₁V20 fusion protein, which is expressed at high levels and readily purified, has been shown to induce significant antibody responses in New Zealand White rabbits (G. Wasserman, personal communication) and *Saimiri sciureus boliven-sis*.¹¹

Studies in our laboratory with a related fusion protein, R32NS1₈₁ (composed of 32 tetrapeptide repeats from the *P. falciparum* repeat region expressed as a fusion protein containing the same 81 amino acids from NS1), showed that BALB/c mice, which are nonresponders to R32 when expressed as R32NS1₈₁, are capable of developing high titers of antibodies to the *P. falciparum* repeat epitopes after they have been exposed to and have seroconverted to the A/PR/8/3 strain of influenza A. This suggests that prior infection with influenza A may enhance the antibody response to the malaria repeat epitopes presented with NS1₈₁. Preliminary safety, immunogenicity, and efficacy studies in humans indicated that




FIGURE 1. Antibody response to PVSV-1 as measured by ELISA. Results are reported in OD units, i.e., that serum dilution that would result in an absorbance of 1 at 414 nm in our standard ELISA. Doses of vaccine were administered at 0, 7, and 15 weeks.

R32NS1₈₁ was safe, well tolerated, and able to induce partial protection against sporozoite challenge as manifested by a delay in the pre-patency period in individuals exposed to *P. falciparum* using a laboratory developed challenge model (J. E. Egan, WRAIR, personal communication).

Based on the above information, we considered NS1₈₁V20 to be a good candidate for a human *P. vivax* sporozoite vaccine. We now report the results of a study in human volunteers to evaluate the safety and immunogenicity of alum-adsorbed NS1₈₁V20, referred to as *P. vivax* sporozoite vaccine 1 (PVSV-1).

MATERIALS AND METHODS

Study subjects

Volunteers were recruited under a protocol approved by The Army Surgeon General's Human Subjects Research Review Board. Healthy men

and women, ages 18–50 years, underwent a medical history (with special attention to a previous history of malaria or splenectomy), physical examination, and routine standard laboratory tests, including complete blood count, serum biochemistries (serum creatinine, blood urea nitrogen, bilirubin, alanine aminotransferase, and aspartate aminotransferase), urinalysis, serum β -HCG for females, hepatitis B surface antigen, serologic test for HIV infection, 2 malaria antibody tests, sporozoite antibodies as measured by ELISA, and blood stage antibodies measured by an indirect fluorescent antibody (IFA) test using red blood cells infected with *P. cynomolgi* as antigen. All tests were performed within 2 weeks before immunization. Subjects were excluded from participation if they had been in a malarious area within 1 year of the start of the study, if they had previously had vivax malaria as determined by history, if the malarial antibody tests were positive, if they had had a splenectomy, or if they had had any cardiovascular, hepatic, renal, or immunological illness, or were taking any immunosuppressive medications. Thirteen volunteers, 7 males and 6 females, meeting the above criteria gave informed consent and entered this study.

Vaccine preparation

NS1₈₁V20 is a 26,692 dalton, single chain polypeptide of 265 amino acids with the following sequence:

```
MDPNTVSSFQ VDCFLWVRKR
VADQELGDAF
LDRLRRDQKS LRGRGSTLGL
DIETATRAGKQ
IVERILKEES DEALKMTMQI P
(GDRADGQPA)4 (GDRAAGQPA)1
(GDRADGQPA)4 (GDRAAGQPA)2
(GDRADGQPA)1 (GDRAAGQPA)1
(GDRADGQPA)1 (GDRAAGQPA)1
(GDRADGQPA)1 (GDRAAGQPA)4
```

NS1₈₁V20 was produced by inserting a BstNI-MnII restriction enzyme fragment encoding the repeat domain of the *P. vivax*, Salvador I (Sal-1) strain, CS protein coding sequence into a vector which expresses 81 amino acids of the NS1 non-structural protein of A/PR/8/34 (H1N1) influenza virus, creating the plasmid pNS1₈₁V20. An *E. coli* expression strain, a derivative of the standard NIH *E. coli* K12 strain N99 (F⁺-su⁻galK2lacZ⁻thr⁻), was then transformed

with pNS1₈₁V20 and used to produce the initial cell paste. Subsequently, crude NS1₈₁V20 was obtained, following the mechanical disruption of the cells, by a series of precipitation steps with polyethyleneimine, ammonium sulfate, and acidic pH conditions. Further purification of NS1₈₁V20 consisted of ion exchange chromatography on sulfopropyl-sepharose, size exclusion chromatography on superose 12, and reversed-phase high performance liquid chromatography on Vydac C-4 packing. Homogeneity of the final product was confirmed by immunoblot analysis with antisera directed against NS1 and a Mab specific for the *P. vivax* repeat region, analytical size exclusion, and RP-HPLC.

NS1₈₁V20 was supplied by SmithKline Beecham Pharmaceuticals, Swedeland, PA, as a 4-vial multi-pack designated *P. vivax* sporozoite vaccine 1 (PVS-1). Vial no. 1 contained 0.4 ml of the NS1₈₁V20 antigen solution at 7 mg/ml in a 50 mM acetate buffer, pH 5.5. Vials nos. 2A and 2B contained the diluent (50 mM acetate buffer, pH 5.5) supplied in 2 sizes, 1.8 ml/vial (no. 2A) and 19.8 ml/vial (no. 2B). Vial no. 3 contained the adjuvant suspension consisting of 0.5 ml of 4.4 mg/ml aluminum oxide (2.2 mg/ml Al⁺⁺⁺) in 50 mM acetate buffer, pH 5.5, with 0.005% w/v thimerosal as a bactericide. The system is such that a 0.5 ml dose containing either 10, 100, or 1,000 µg of NS1₈₁V20 and 2.2 mg of aluminum oxide could easily be made just prior to administration. All components of PVS-1 were stored at 4°C prior to use.

Immunization schedule

Volunteers were randomly assigned to 1 of 3 groups and received either 10, 100, or 1,000 µg of NS1₈₁V20 as PVS-1 im at week 0, with identical booster doses being given at 7 and 15 weeks. Volunteers were observed for 20 min after each dose for immediate reactions and evaluated at 24 and 48 hr for symptoms of headache, fever, chills, malaise, local pain, fever, erythema, warmth, induration, lymphadenopathy, and other complaints. Prior to and again 2 days after each dose of vaccine, each volunteer had blood and urine collected for evaluation. Serum samples were obtained each week for 3 weeks after each dose. Whole blood was allowed to clot at room temperature, serum was separated and stored at -70°C until analyzed.

Serological assays

CS antibodies were measured using a standard ELISA technique^{12,13} except that a recombinant protein, referred to as VIVAX-1, which contained the entire repeat region of *P. vivax* flanked by the 15 amino acids amino terminal and the 48 amino acids carboxy-terminal of the repeats, was used as the capture antigen.¹⁴ This molecule does not contain the NS1₈₁ segment present in PVS-1. Horseradish-peroxidase conjugated rabbit anti-human IgG (gamma chain specific) was used as the secondary antibody. Assays were run in triplicate and the mean absorbance and standard deviation was calculated for each dilution.

Immunofluorescence assays were performed as previously described.¹² Hand dissected salivary-gland sporozoites from the Sal-1 strain of *P. vivax* were suspended in Medium 199, containing 0.01% (v/v) bovine serum albumin, dotted onto multi-well immunofluorescence assay slides at 10,000 sporozoites/dot, air-dried at room temperature, and stored at -70°C until used. Antibodies reactive to sporozoites were detected with fluorescein-labeled anti-human IgG under ultraviolet light at 500× magnification. Fluorescence was graded from 0 to +4, where 0 indicates no fluorescence detectable and +4 indicates intense fluorescence over the entire surface of the sporozoite.

Percent inhibition of sporozoite invasion of HepG2A-16 human hepatoma cells in vitro was calculated according to Hollingdale.¹⁵

RESULTS

The 13 individuals (mean age 35 years, range 22-44 years), were randomly divided into 3 groups to receive PVS-1. The vaccine was well-tolerated by all. The major side effect noted was minor discomfort at the injection site in all volunteers, which resolved within 24 hr. Two individuals in the 1,000 µg dose group noted the onset of malaise and generalized myalgias 6-9 hr after the administration of the second dose of vaccine. These symptoms resolved after 48 hr. One of these individuals continued in the study, receiving the third dose of vaccine as scheduled, and experienced no untoward reaction, suggesting that the previous reaction was not causally related to the vaccine. There were no abnormalities in blood chemistry, hematology profiles,

TABLE 1
IFA results

Volunteer no.	Week 2	Week 9	Week 17
6	25	0	0
7	100	50	50
8	50	400	200
9	100	50	100
10	100	100	100

Results represent the highest serum dilution which produced a 2+ IFA reaction.

or urinalysis attributable to vaccine administration.

Six of the 9 volunteers who received either the 100 or 1,000 μ g dose of PVS-1 developed antibodies to the vivax repeat epitopes as measured by ELISA (Fig. 1). Four of the individuals receiving the 100 μ g dose had an initial response after the first dose of vaccine, but failed to demonstrate any boosting with subsequent doses. Volunteer no. 8 demonstrated a minor response to the first dose of vaccine, which returned to baseline by week 4. This volunteer demonstrated a response after the second dose of vaccine, but not after the third dose of vaccine. Only 1 individual (no. 14) in the 1,000 μ g dose group seroconverted. This volunteer showed an initial response to the vivax epitope, but antibody levels failed to rise after the second dose of vaccine. She withdrew from the study because of malaise and generalized myalgias after the second dose of vaccine.

Sera from week nine from volunteers in groups A and C were negative by IFA, while the IFA results from volunteers in Group B paralleled those measured by ELISA (Table 1). None of the volunteers developed antisera capable of inhibiting sporozoite invasion of HepG2-A1G cells in vitro.

DISCUSSION

Mabs directed against the repeat region of CS proteins can passively transfer protection against sporozoite challenge. This fact provides compelling rationale for the development of anti-sporozoite malaria vaccines designed to induce high levels of anti-CS antibody. Early studies with *P. falciparum* subunit vaccines supported this approach, although the degree of protection achieved was suboptimal.^{6,7} In an analogous manner, we have developed a recombinant *P. vivax* subunit vaccine designed to induce anti-

bodies to the immunodominant repeat region of the *P. vivax* CS protein. This study demonstrates that the recombinant fusion protein NS1₈₁V20 is safe and well tolerated when administered to normal male and female volunteers in doses up to 1,000 μ g. Somewhat surprising, however, was the lack of a classical anamnestic response to subsequent doses of the vaccine and the lack of a typical dose response with increasing amounts of antigen. The data obtained using NS1₈₁V20 suggest the possibility of an immunosuppressive epitope in the repeating (GDRA D/A GQPA) region of the *P. vivax* CS protein. The implication of less than optimal immune responses reflected in these data, combined with the recently reported discovery of *P. vivax* isolates from Thailand which produce sporozoites that possess a CS protein with significant differences in the repeat region,¹⁶ may complicate efforts to develop a *P. vivax* anti-sporozoite vaccine based solely on the immunodominant region of the CS protein.

Acknowledgments: We would like to thank Vidal de la Cruz for supplying the *P. vivax* CS protein coding sequence, William Collins, Center for Disease Control, Atlanta, GA for supplying *P. vivax*-infected mosquitoes, and the Chiron Corporation for the the VIVAX-1 antigen.

Authors' addresses: Daniel M. Gordon and Jeffrey D. Chulay, Department of Immunology, and Imogene Schneider, Department of Entomology, Walter Reed Army Institute of Research, Washington, DC 20307. Thomas M. Cosgriff, Department of Medicine, United States Army Medical Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21701. Gail F. Wasserman, Department of Biological Process Sciences, and William R. Majarian, Department of Molecular Biology, SmithKline Beecham Pharmaceuticals, Swedeland, PA. Michael R. Hollingdale, Biomedical Research Institute, Rockville, MD.

Reprint requests: Daniel M. Gordon, Department of Immunology, Walter Reed Army Institute of Research, Washington, DC 20307-5100.

REFERENCES

1. Nussenzweig R, Vanderberg J, Most H, 1969. Protective immunity produced by the injection of x-irradiated sporozoites of *Plasmodium berghei*. IV. Dose response, specificity and humoral immunity. *Milit Med* 134: 1176-1182. UI:70208847
2. Gwadz RW, Cochrane AH, Nussenzweig V, Nussenzweig RS, 1979. Preliminary studies on vaccination of rhesus monkeys with irradiated spo-

- rozoites of *Plasmodium knowlesi* and characterization of surface antigens of these parasites. *Bull World Health Organ (Suppl 1)* 57: 165-173. UI:80177289
3. Clyde DF, McCarthy VC, Miller RM, Woodward WE, 1974. Characteristics of *Plasmodium falciparum* from the Solomon Islands. *J Trop Med Hyg* 77: 9-12. UI:74090361
 4. Potocnjak P, Yoshida N, Nussenzweig RS, Nussenzweig V, 1980. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. *J Exp Med* 151: 1504-1513. UI: 80205803
 5. Egan JE, Weber JL, Ballou WR, Hollingdale MR, Majarian WR, Gordon DM, Maloy WL, Hoffman SL, Wirtz RA, Schneider I, and others, 1987. Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development. *Science* 236: 453-456. UI:87178024
 6. Ballou WR, Hoffman SL, Sherwood JA, Hollingdale MR, Neva FA, Hockmeyer WT, Gordon DM, Schneider I, Wirtz RA, Young JF, and others, 1987. Safety and efficacy of a recombinant DNA *Plasmodium falciparum* sporozoite vaccine. *Lancet* i: 1277-1281. UI:87227707
 7. Herrington DA, Clyde DF, Losonsky G, Cortesia M, Murphy JR, Davis J, Baqar S, Felix AM, Heimer EP, Gillesen D, and others, 1987. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against *Plasmodium falciparum* sporozoites. *Nature* 328: 257-259. UI: 87258256
 8. Arnot DE, Barnwell JW, Tam JP, Nussenzweig V, Nussenzweig RS, Enea V, 1985. Circumsporozoite protein of *Plasmodium vivax*: gene cloning and characterization of the immunodominant epitope. *Science* 230: 815-818. UI: 86044510
 9. McCutchan TF, Lal AA, de la Cruz VF, Miller LH, Maloy WL, Charoenvit Y, Beaudoin RL, Guerry P, Wistar R Jr, Hoffman SL, and others, 1985. Sequence of the immunodominant epitope for the surface protein on sporozoites of *Plasmodium vivax*. *Science* 230: 1381-1383. UI:86070222
 10. Yamada A, Ziese MR, Young JF, Yamada YK, Ennis FA, 1985. Influenza virus hemagglutinin-specific cytotoxic T cell response induced by polypeptide produced in *Escherichia coli*. *J Exp Med* 162: 663-674. UI:85263418
 11. Collins WE, Nussenzweig RS, Ballou WR, Ruebush TK, Nardin EH, Chulay JD, Marjarian WR, Young JF, Wasserman GF, Young JF, and others, 1989. Immunization of *Saimiri sciureus boliviensis* monkeys with recombinant vaccines based on the circumsporozoite protein of *Plasmodium vivax*. *Am J Trop Med Hyg* 40: 455-464.
 12. Wirtz RA, Ballou WR, Schneider I, Chedid L, Gross MJ, Young JF, Hollingdale M, Diggs CL, Hockmeyer WT, 1987. *Plasmodium falciparum*: immunogenicity of circumsporozoite protein constructs produced in *Escherichia coli*. *Exp Parasitol* 63: 166-172. UI:87190839
 13. Young JF, Hockmeyer WT, Gross M, Ballou WR, Wirtz RA, Trosper JH, Beaudoin RL, Hollingdale MR, Miller LH, Diggs CL, and others, 1985. Expression of *Plasmodium falciparum* circumsporozoite proteins in *Escherichia coli* for potential use in a human malaria vaccine. *Science* 228: 958-962. UI:85218767
 14. Barr PJ, Gibson HL, Enea V, Arnot DE, Hollingdale MR, Nussenzweig V, 1987. Expression in yeast of a *Plasmodium vivax* antigen of potential use in a human malaria vaccine. *J Exp Med* 165: 1160-1171. UI:87168195
 15. Hollingdale MR, Nardin EH, Tharavanij S, Schwartz AL, Nussenzweig RS, 1984. Inhibition of entry of *Plasmodium falciparum* and *P. vivax* sporozoites into cultured cells: an in vitro assay of protective antibodies. *J Immunol* 132: 909-913. UI:84089021
 16. Rosenberg R, Wirtz RA, Lanar DE, Sattabongkot J, Hall T, Waters AP, Prasittisuk C, 1989. Circumsporozoite protein heterogeneity in the human malaria parasite *Plasmodium vivax*. *Science* 245: 973-976. UI:89368927

Accession For	
NTIS CRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution /	
Availability Codes	
Dist	Avail and/or Special
A-1	20

